肝细胞癌是美国肝移植和等待名单登记最常见的适应证
该回顾性研究基于美国器官共享联合网络/器官获取与移植网络登记数据,分析了2004年1月1日至2015年12月31日所有成人肝移植登记患者。2015年肝细胞癌是登记(23.9%)和移植受者(27.2%)中最常见的诊断;2011-2014年期间肝细胞癌登记患者接受肝移植的概率降低(HR 0.62),而移植前和移植后结局改善,尤其在丙型肝炎病毒感染患者中。
要点
- 2015年肝细胞癌是肝移植登记和受者中最常见的诊断。
- 2004-2015年肝细胞癌与非肝细胞癌登记比值在丙型肝炎、乙型肝炎、酒精滥用和非酒精性脂肪性肝炎患者中分别增加5.6倍、1.9倍、2.7倍和10.2倍。
- 2011-2014年期间肝细胞癌登记患者接受肝移植的概率降低(HR 0.62,P<.0001)。
核心结论
- 2015年肝细胞癌是美国肝移植最常见的适应证,但肝细胞癌登记患者接受肝移植的概率下降最明显,移植前和移植后结局改善,尤其在丙型肝炎病毒感染患者中。
研究设计与样本
- 回顾性研究,使用美国器官共享联合网络/器官获取与移植网络登记数据,纳入2004年1月1日至2015年12月31日所有成人肝移植登记患者,共109,018例登记。
主要发现
- 109,018例登记中18.5%因肝细胞癌登记;2015年肝细胞癌占登记的23.9%和移植受者的27.2%。
- 2004-2015年肝细胞癌与非肝细胞癌登记比值在丙型肝炎患者增加5.6倍、乙型肝炎患者增加1.9倍、酒精滥用患者增加2.7倍、非酒精性脂肪性肝炎患者增加10.2倍。
- 调整协变量后,2011-2014年期间与肝细胞癌登记患者接受肝移植概率降低相关(HR 0.62,P<.0001)。
- 2011-2014年期间与因病情恶化或死亡退出等待名单概率降低相关:丙型肝炎肝病(HR 0.90,P=.0003)、乙型肝炎肝病(HR 0.71,P=.002)、酒精性肝病(HR 0.90,P=.01)。
- 2011-2014年期间与因临床改善剔除等待名单概率增加相关:丙型肝炎感染(HR 3.4,P<.0001)、乙型肝炎感染(HR 2.3,P=.004)、酒精滥用(HR 2.2,P<.0001);与移植物丢失或死亡风险降低相关,丙型肝炎感染受者效应最大(HR 0.76,P<.0001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Management strategies for patients with hepatitis C virus (HCV) infection and hepatocellular carcinoma (HCC) have changed, along with liver allocation policies based on model for end-stage liver disease score. We investigated etiologic-specific trends in liver transplantation in the United States during different time periods. METHODS: We performed a retrospective study, using the United Network for Organ Sharing/Organ Procurement and Transplantation Network registry data, to identify all adult patients registered for liver transplantation in the United States from January 1, 2004, through December 31, 2015. For subjects listed with multiple diagnoses, HCC was considered the primary listing diagnosis. To determine whether availability of direct-acting antiviral agents, which began in 2011, affected pretransplant (death or drop-out) and post-transplant outcomes for patients with HCV infection, we compared data from the time periods of 2004 to 2010 and 2011 to 2014. We used competing-risk analysis to compare differences in end points between these periods. Differences between periods in pretransplantation and post-transplantation outcomes were estimated using Kaplan-Maier analysis and compared using the log-rank test. Associations between year of listing and pre-liver transplant outcome, and year of liver transplant and survival after transplant, were examined using the log-rank test. Proportional hazard regression was used to evaluate the reliability of the time period effect with potential confounders. RESULTS: Among 109,018 registrants, 18.5% were registered for liver transplantation because of HCC. In 2015, HCC was the leading diagnosis among registrants (23.9% of registrations) and recipients (27.2% of recipients). Between 2004 and 2015, the ratio of registrants with vs without HCC increased 5.6-fold for patients with HCV infection, 1.9-fold for patients with hepatitis B virus (HBV) infection, 2.7-fold for patients with alcohol abuse, and 10.2-fold for patients with nonalcoholic steatohepatitis. After adjusting for covariates, we associated the period of 2011 to 2014 with a decreased probability that HCC registrants would undergo liver transplantation (hazard ratio [HR], 0.62; P < .0001). The period of 2011 to 2014 also was associated with a decreased probability of drop-out owing to deterioration or death from HCV-induced (HR, 0.90; P = .0003), HBV-induced (HR, 0.71; P = .002), or alcohol-induced (HR, 0.90; P = .01) liver disease, and an increased probability of delisting as a result of clinical improvement in patients with HCV infection (HR, 3.4; P < .0001), HBV infection (HR, 2.3; P = .004), or alcohol abuse (HR, 2.2; P < .0001). The period of 2011 to 2014 was associated with a decreased risk of graft loss or death, with the largest effect seen in HCV-infected recipients (HR, 0.76; P < .0001). CONCLUSIONS: HCC was the leading indication for liver transplantation in the United States in 2015. Despite this, the probability of liver transplantation decreased the most in registrants with HCC. Pretransplantation and post-transplantation outcomes have improved, particularly in patients with HCV infection.
引用
- Yang JD, Larson JJ, Watt KD, et al. Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States. Clin Gastroenterol Hepatol. 2016. PMID: 28013117. doi:10.1016/j.cgh.2016.11.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。